Whole-body tumor imaging using PET and 2-18F-fluoro-l-tyrosine: Preliminary evaluation and comparison with 18F-FDG

Journal of Nuclear Medicine

Volumn 44, Issue 4, 2003, Pages 533-539

  Hustinx, Roland ^a,c   Lemaire, Christian ^b   Jerusalem, Guy ^a   Moreau, Pierre ^a   Cataldo, Didier ^a   Duysinx, Bernard ^a   Aerts, Joel ^b   Fassotte, Marie France ^a   Foidart, Jacqueline ^a   Luxen, André ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c CHU SART TILMAN   (Belgium)

Author keywords

2 18F fluoro l tyrosine; 18F FDG*PET; Cancer; Protein synthesis

Indexed keywords

2 FLUOROTYROSINE F 18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT;

ARTICLE; BONE MARROW; CALCULATION; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; EVALUATION; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INJECTION; LIVER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM; MUSCLE; PANCREAS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STANDARD; STRUCTURE ANALYSIS; TIME; TUMOR; AGED; ANTIBODY SPECIFICITY; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEASIBILITY STUDY; FEMALE; HEAD AND NECK TUMOR; LUNG TUMOR; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NEOPLASM; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; WHOLE BODY COUNTING;

AGED; AGED, 80 AND OVER; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING;

EID: 0038654385     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32:35-46.
2. Hofer C, Kubler H, Hartung R, Breul J, Avril N. Diagnosis and monitoring of urological tumors using positron emission tomography Eur Urol. 2001;40:481-487
3. Strauss LG. Fluonne-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 1996;23:1409-1415.
4. Isselbacher KJ. Sugar and ammo acid transport by cells in culture: differences between normal and malignant cells. N Engl J Med. 1972;286:929-933.
5. 11C]methionine for measuring in vivo protein synthesis rates with PET. J Nucl Med. 1988;29:1419-1427.
6. 11C]methionine. Jpn J Cancer Res. 1989;80:778-782.
7. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445.
8. 18F]fluorotyrosine, a new PET tracer of protein synthesis. J Nucl Med. 1989;30:1367-1372.
9. 18F)fluorotyrosine. J Nucl Med. 1991;32: 1338-1346.
10. 18F]fluoro-L-tyrosine by catalytic phase-transfer alkylation. J Labelled Compds Radiopharm. 2001;44:S857-S859.
11. Ooi T, Kameda M, Maruoka K Molecular design of a C2-symmetric chiral phase transfer catalysis for practical asymmetric synthesis of α-amino acids. J Am Chem Soc. 1999;121:6519-6520.
12. 18F]FDG synthesis by alkaline hydrolysis on a low polarity solid phase support. J Labelled Compds Radiopharm. 2002;45:435-447.
13. Adam LE, Karp JS, Daube-Witherspoon ME, Smith RJ. Performance of a whole-body PET scanner using curve-plate NaI(Tl) detectors. J Nucl Med. 2001;42:1821-1830.
14. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999;213:521-525.
15. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863-871.
16. Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med. 2002;32:47-59.
17. Laverman P, Boerman OC, Corstens FH, Oyen WJ. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging. 2002;29:681-690.
18. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778-785.
19. 11C]methionine in human plasma. Eur J Nucl Med. 1989;15:665-669
20. 11C]tyrosme imaging of soft-tissue tumors before and after therapy. J Nucl Med. 1999;40:381-386.
21. Kole AC, Pruim J, Nieweg OE, et al. PET with L-[1-carbon-11]tyrosine to visualize tumors and measure protein synthesis rates. J Nucl Med. 1997;38:191-195.
22. 11C]tyrosine positron emission tomography correlates with mitotic activity and MIB-1 antibody-detected proliferation in human soft tissue sarcomas. Eur J Nucl Med. 1999;26:328-332.
23. 11C]tyrosine PET. J Nucl Med. 1997;38:692-696.
24. Pruim I, Willemsen AT, Molenaar WM, et al. Brain tumors: L-[1-C-11]tyrosine PET for visualization and quantification of protein synthesis rate. Radiology. 1995;197:221-226
25. Kole AC, Hoekstra HJ, Sleijfer DT, Nieweg OE, Schraffordt Koops H. Vaalburg W. L-[1-carbon-11]tyrosine imaging of metastatic testicular nonseminoma germ-cell tumors. J Nucl Med. 1998;39:1027-1029.
26. Müller-Hermelink HK, Zettl A, Pfeifer W, Ott G. Pathology of lytnphoma progression. Histopathology. 2001;38:285-306.
27. de Boer JR, van der Laan BFM, Pruim J, et al. Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas. Eur J Nucl Med Mol Imaging. 2002;29:1182-1187.
28. Kubota R, Kubota K, Yamada S, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG J Nucl Med. 1995;36:484-492.
29. Kubota K, Kubota R, Yamada S, Tada M. Effects of radiotherapy on the cellular uptake of carbon-14 labeled L-methionine in tumor tissue. Nucl Med Biol. 1995;22:193-198.
30. Nettelbladt OS, Sundin AE, Valind SO, et al. Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum. J Nucl Med 1998;39:640-647.
31. 18F]fluoroethyl)-L- tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol imaging. 2002;29:1039-1046.
32. 18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med. 1999;40:1367-1373.
33. 18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol. 1993;20:895-899.
34. Ishiwata K, Kubota K, Murakami M, et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med. 1993;34:1936-1943.
35. 11C-methionine in breast cancer studied by PET: an association with the size of S-phase fraction. Br J Cancer 1991;64:1121-1124.
36. Miyazawa H, Arai T, Iio M, Hara T. PET imaging of non-small-cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters J Nucl Med. 1993;34:1886-1891.
37. Bading JR, Kan-Mitchell J, Conti PS. System A amino acid transport in cultured human tumor cells: implications for tumor imaging with PET. Nucl Med Biol. 1996;23:779-786.
38. Ishiwata K, Enomoto K, Sasaki T, et al. A feasibility study on L-[1-carbon-11]tyrosine and L-[methyl-carbon-11]methionine to assess liver protein synthesis by PET. J Nucl Med. 1996;37:279-285.